We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Jazz Pharma Wins Idiopathic Hyperinsomnia Indication for Xywav
Jazz Pharma Wins Idiopathic Hyperinsomnia Indication for Xywav
Jazz Pharmaceuticals’ Xywav (calcium, magnesium, potassium, and sodium oxybates), already approved for narcolepsy, has won a new indication as a treatment for idiopathic hypersomnia (IH) in adults.